

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

DECICCO ET AL

APPLICATION NO.: 09/783,248



CASE NO.: PH-7064

FILED: FEBRUARY 14, 2001

GROUP ART UNIT: UNKNOWN

EXAMINER: UNKNOWN

FOR: MATRIX METALLOPROTEINASE INHIBITORS

WILMINGTON, DELAWARE  
July 27, 2001INFORMATION DISCLOSURE STATEMENT

Box DD

Hon. Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b). Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1).

Please charge any deficiency or credit any overpayment to Deposit Account No. 04-1928.

There are no listed references that are not in the English language or do not contain an English language abstract.

Respectfully submitted,

Peter L. Dolan, Ph.D.  
Agent for Applicants  
Registration No. 46,307  
Telephone 302 - 992-4528

#4

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**Complete if Known****INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

JUL 30 2001

(use as many sheets as necessary)

Sheet

1

of

2

Application Number	09/783,248
Filing Date	February 14, 2001
First Named Inventor	Carl P. Decicco
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	PH-7064

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
		5,382,654		Lyle et al		
		5,556,939		Flanagan et al		
		5,650,134		Albert et al		
		5,674,754		Ahrens et al.		
		6,172,057		Venkatesan et al.		

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Baker, et al. Life Sci., 1991, 49, 1583-91	
		Garbisa et al., 1992, Cancer Res., 53, 4548	
		Matthes et al., 1992, Gastroenterology, Abstract 661	
		Anthony et al., 1992, Gastroenterology, Abstract 591	
		Walakovits et al., 1992, Arth. Rheum., 35, 35	
		Zucker et al., 1993, Cancer Res. 53, 140	
		Krenning, et al., 1993, Eur. J. Nucl. Med., 20, 716-31	
		Curr. Opin. Ther. Patents 1994 4, 1, 7-16	
Examiner Signature		Date Considered	

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

→ +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
is exempted from a collection of information where it contains our ETD-CWD control number.

**Substitute for form 1449A/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	09/783,248
Filing Date	February 14, 2001
First Named Inventor	Carl P. Decicco
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	PH-7064

#### **OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Exp. Opin. Ther. Patents <b>1995</b> <i>5</i> , 2, 1087-1100	
		Exp. Opin. Ther. Patents <b>1995</b> <i>5</i> , <b>12</b> , 1287-1196	
		Curr. Medicinal Chem. <b>1995</b> , <i>2</i> , 743-762	
		Krenning, et al., <b>1996</b> , Digestion, <b>57</b> , 57-61	
		Beckett et al. <b>1996</b> , Research Focus, <i>1</i> , 16-26	
		Summers, et al, Annual reports in Med. Chem., <b>1998</b> , <i>33</i> , 131	
		Stein et al., <b>1999</b> , Clin. Cancer Res., <i>5</i> , 3199s-3206s,	
		Whittaker. et al, Chem. Rev., <b>1999</b> , <i>99</i> , 2735-2776	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.